Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Coagulation01:09

Coagulation

8.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.7K
Coagulation01:06

Coagulation

571
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
571
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the bone marrow microenvironment by acute B-cell lymphoblastic leukemia-derived large oncosomes.

Blood advances·2026
Same author

Chronic Erythrocyte NO Production Accelerates Atherosclerosis by Increasing SMC De Novo Lipogenesis.

Circulation research·2026
Same author

Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting.

Nature communications·2024
Same author

Barrier disruption by coagulation FXIa.

Blood·2024
Same author

Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes.

Blood·2024
Same author

Exposure to aircraft noise exacerbates cardiovascular and oxidative damage in three mouse models of diabetes.

European journal of preventive cardiology·2024

Related Experiment Video

Updated: Nov 8, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K

Roles of factor Xa beyond coagulation.

Wolfram Ruf1,2

  • 1Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical Center, Langenbeckstr. 1, 55131, Mainz, Germany. ruf@uni-mainz.de.

Journal of Thrombosis and Thrombolysis
|April 24, 2021
PubMed
Summary

Coagulation factor Xa (FXa) plays a crucial role beyond blood clotting, influencing inflammation and cancer. Targeting FXa offers potential therapeutic benefits by reprogramming immune cells in various diseases.

Keywords:
Coagulation factor XaProtease activated receptorsTissue factor pathway

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.0K

Related Experiment Videos

Last Updated: Nov 8, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.0K

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Coagulation factor Xa (FXa) is a target for thromboprophylaxis.
  • The tissue factor (TF) pathway, involving TF-FVIIa complex activation of FX, is central to thrombosis and hemostasis.
  • FXa has emerging roles beyond coagulation, influencing immune reactions.

Purpose of the Study:

  • To elucidate the distinct functions of circulating versus tissue-synthesized coagulation factors.
  • To understand the broader roles of FXa in immune and hematopoietic systems.
  • To explore FXa's signaling functions mediated through protease-activated receptor 2 (PAR2) in extravascular environments.

Main Methods:

  • Investigating FXa's interaction with TF-FVIIa complex.
  • Analyzing FXa-mediated PAR2 activation by macrophages.
  • Evaluating the impact of oral FXa inhibitors on tumor-associated macrophages.

Main Results:

  • FXa associated with TF-FVIIa supports cofactor VIII activation.
  • FXa signaling via PAR2, particularly by macrophage-synthesized FX, influences inflammation, cancer, and autoimmunity.
  • FXa-PAR2 signaling promotes tumor-associated macrophage polarization.
  • Oral FXa inhibitors can reprogram tumor-associated macrophages for non-coagulant therapeutic effects.

Conclusions:

  • FXa is a critical regulator of both hemostasis and immune responses.
  • Distinguishing hepatic and extrahepatic FXa functions is essential for therapeutic development.
  • Targeting FXa offers potential for treating inflammatory, autoimmune, and cancerous diseases through immune modulation.